retatrutide safety trial results (LY-3437943) Market Analysis, 2033: Triple-Agonist Therapy Landscape In Obesity And Metabolic Disorders VisualAbstract: Retatrutide reduces body weight

Type 2 diabetes mellitus (T2DM) is a major risk factor for cardiovascular disease

Since 2024, we've worked with @EliLillyandCo to expand access to FDA-approved GLP-1s, and this is another step toward making treatment simpler and more seamless for patients

Congratulations to Eli Lilly and the broader obesity treatment community

A 2026 analysis of 25 products found zero contained semaglutide

Prime Labs Semaglutide is supplied exclusively for scientific research and in-vitro study

Please consult your physician before use if you are pregnant or nursing, under the age of 18, or are undergoing treatment for a medical condition